Data from Bowel Cancer UK - Curated by EPG Health - Date added 28 March 2018

 

April is Bowel Cancer Awareness Month (BCAM), a fantastic annual opportunity to raise awareness of bowel cancer and funds to support Bowel Cancer UK’s work.

This year, Beating Bowel Cancer and Bowel Cancer UK have merged to form the UK’s leading bowel cancer charity, with a mission to ensure that by 2050, no-one will die of bowel cancer.

Bowel cancer is the UK’s second biggest cancer killer; however, it shouldn’t be because it is treatable and curable especially if diagnosed early. Nearly everyone diagnosed at the earliest stage will survive bowel cancer, but this drops significantly as the disease develops.

Someone dies from bowel cancer in the UK every thirty minutes.  Seems unthinkable doesn’t it, especially when bowel cancer is treatable when diagnosed at an early stage.  The only problem is that only 9% of patients are diagnosed at the early stage.

Some of the common symptoms of bowel cancer include:

  • Bleeding from the bottom and blood in poo
  • Persistent and unexplained change in bowel habit
  • Sudden and unexplained weight loss
  • Being easily fatigued with no obvious reason or cause
  • Pain or a lump in the tummy

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content